Patents by Inventor John E. Starrett, Jr.

John E. Starrett, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10174024
    Abstract: The present invention is directed to tricyclic compounds of formula (I), pharmaceutically acceptable compositions comprising compounds of the invention and said compositions for use in methods for the treatment of various disorders in particular cancer.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: January 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wen-Ching Han, Andrew P. Degnan, Jeffrey A. Deskus, Ashvinikumar V. Gavai, Patrice Gill, William D. Schmitz, John E. Starrett, Jr.
  • Publication number: 20180093983
    Abstract: The present invention is directed to tricyclic compounds of formula (I), pharmaceutically acceptable compositions comprising compounds of the invention and said compositions for use in methods for the treatment of various disorders in particular cancer.
    Type: Application
    Filed: May 11, 2016
    Publication date: April 5, 2018
    Inventors: Wen-Ching HAN, Andrew P. Degnan, Jeffrey D. Deskus, Ashvinikumar V. Gavai, Patrice Gill, William D. Schmitz, John E. Starrett, JR.
  • Patent number: 9751879
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, Jr., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Patent number: 9725449
    Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 8, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, Wayne Vaccaro, Mikkel V. DeBenedetto, Andrew P. Degnan, George V. Delucca, Jeffrey A. Deskus, Wen-Ching Han, Godwin Kwame Kumi, William D. Schmitz, John E. Starrett, Jr., Matthew D. Hill, Hong Huang
  • Publication number: 20160333013
    Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 10, 2016
    Publication date: November 17, 2016
    Inventors: Derek J. Norris, Wayne Vaccaro, Mikkel V. DeBenedetto, Andrew P. Degnan, George V. Delucca, Jeffrey A. Deskus, Wen-Ching Han, Godwin Kwame Kumi, William D. Schmitz, John E. Starrett, JR., Matthew D. Hill, Hong Huang
  • Publication number: 20160326173
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 10, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Publication number: 20160318928
    Abstract: The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 3, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Publication number: 20160176864
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: June 23, 2016
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, JR., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • Patent number: 8350084
    Abstract: The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with ?-amyloid peptide.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: January 8, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Starrett, Jr., Kevin W. Gillman, Richard E. Olson, Lawrence R. Marcin, Bang-Chi Chen, Huiping Zhang
  • Publication number: 20120088925
    Abstract: The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with ?-amyloid peptide.
    Type: Application
    Filed: November 18, 2011
    Publication date: April 12, 2012
    Inventors: John E. Starrett, JR., Kevin W. Gillman, Richard E. Olson, Lawrence R. Marcin, Bang-Chi Chen, Huiping Zhang
  • Patent number: 8093276
    Abstract: The present invention provides a method for the treatment of head trauma, traumatic brain injury, and/or dementia pugilistica comprising administering a therapeutically effective amount of (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: January 10, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Starrett, Jr., Kevin W. Gillman, Richard E. Olson
  • Patent number: 8084477
    Abstract: The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with ?-amyloid peptide.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: December 27, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Starrett, Jr., Kevin W. Gillman, Richard E. Olson
  • Patent number: 8044077
    Abstract: The present disclosure provides novel deuterated alpha-(N-sulfonamido)acetamide compounds, their pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease, head trauma, traumatic brain injury, and/or dementia pugilistica and/or other conditions associated with ?-amyloid peptide.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: October 25, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Starrett, Jr., Kevin W. Gillman, Richard E. Olson
  • Publication number: 20110071199
    Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R1, R2 and n are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
    Type: Application
    Filed: March 16, 2010
    Publication date: March 24, 2011
    Inventor: John E. Starrett, JR.
  • Publication number: 20100240719
    Abstract: The present disclosure provides novel deuterated alpha-(N-sulfonamido)acetamide compounds, their pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease, head trauma, traumatic brain injury, and/or dementia pugilistica and/or other conditions associated with ?-amyloid peptide.
    Type: Application
    Filed: March 15, 2010
    Publication date: September 23, 2010
    Inventors: John E. Starrett, JR., Kevin W. Gillman, Richard E. Olson
  • Publication number: 20090227642
    Abstract: The present invention provides a method for the treatment of head trauma, traumatic brain injury, and/or dementia pugilistica comprising administering a therapeutically effective amount of (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide.
    Type: Application
    Filed: March 19, 2009
    Publication date: September 10, 2009
    Inventors: John E. Starrett, JR., Kevin W. Gillman, Richard E. Olson
  • Publication number: 20090111858
    Abstract: The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with ?-amyloid peptide.
    Type: Application
    Filed: October 10, 2008
    Publication date: April 30, 2009
    Inventors: John E. Starrett, JR., Kevin W. Gillman, Richard E. Olson
  • Patent number: 7169803
    Abstract: The present invention provides novel N-substituted fluorooxindoles having the general Formula I wherein the wavy bond represents the racemate, the (R)-enantiomer or the (S)-enantiomer and m, n, p, q, A, B, D, Q, X, and Z are as defined below, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of potassium channels.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: January 30, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Starrett, Jr., Omar D. Lopez, Piyasena Hewawasam, Min Ding
  • Patent number: 7151180
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: December 19, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Sing-Yuen Sit, John E. Starrett, Jr.
  • Patent number: 7091202
    Abstract: The invention encompasses compounds of Formula I, which are blockers of KCNQ channels. Blockers of KCNQ channels are known to enchance cognition in laboratory animals.
    Type: Grant
    Filed: September 8, 2005
    Date of Patent: August 15, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin W. Gillman, Dharmpal S. Dodd, John E. Starrett, Jr., Danielle Bocchino